Assertio Holdings, Inc. (ASRT)
9.31
-0.12
(-1.27%)
USD |
NASDAQ |
Jan 08, 16:00
9.31
0.00 (0.00%)
After-Hours: 20:00
Assertio Holdings Research and Development Expense (Quarterly): 0.379M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 19.56M |
| Skye Bioscience, Inc. | 9.178M |
| Theravance Biopharma, Inc. | 7.707M |
| FibroGen, Inc. | 1.209M |
| Myomo, Inc. | 1.528M |